β2- 微球蛋白及乳酸脱氢酶检测在多发性骨髓瘤诊治中的价值研究

Abstract: Objective To study the value of β2-microglobulin (β2-MG) and lactate dehydrogenase (LDH) in the diagnosis and treatment of multiple myeloma (MM). Methods 60 cases of MM patients and 60 cases of healthy people in our hospital from February 2024 to February 2025 were selected as the observation objects. The former was included in the observation group and the latter in the control group. The serum levels of β2-MG and LDH were detected in all patients, and the serum levels of β2-MG and LDH were compared between the observation group and the control group. The patients were divided into groups according to the stage and treatment effect, and the levels of serum β2-MG and LDH in each group were compared. Results The levels of serum β2-MG and LDH in the observation group (4.35±1.28) mg/L, (236.42±66.08) U/L were significantly higher than those in the control group (2.81±0.69) mg/L, (162.21±22.35) U/L (t= 8.203, 8.240; P＜0.05). The levels of serum β2-MG and LDH in the observation group at stage Ⅲ (8.95±1.34) mg/L, (315.27±75.38) U/L were significantly higher than those at stage Ⅰ (2.75±0.35) mg/L, (196.08±56.27) U/L, stage Ⅱ (3.96±0.88) mg/L, (256.14±62.19) U/L, and stage Ⅱ was significantly higher than that at stage Ⅰ (P＜0.05). After treatment, the levels of serum β2-MG, LDH, bone marrow plasma cells, serum M protein, blood calcium and urea nitrogen in the observation group were statistically verified. The effective patients in the observation group were lower than the ineffective patients, and the hemoglobin was higher than the ineffective patients (P＜0.05). Conclusion The levels of β2-MG and LDH in MM patients can judge the diagnosis stage and progress of the disease, and the decrease of LDL and β2-MG after treatment indicates the effectiveness of treatment.